Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 4,335 Shares of Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 4,335 shares of the company's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $165.87, for a total transaction of $719,046.45. Following the transaction, the chief financial officer now owns 103,697 shares in the company, valued at approximately $17,200,221.39. This trade represents a 4.01 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The stock was sold at an average price of $176.88, for a total transaction of $7,694,633.76.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total value of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total transaction of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total transaction of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07.

Natera Stock Performance

NASDAQ NTRA traded down $1.86 on Thursday, reaching $175.14. The stock had a trading volume of 742,631 shares, compared to its average volume of 1,351,574. The business's 50-day moving average price is $167.56 and its 200 day moving average price is $140.02. The stock has a market cap of $23.12 billion, a P/E ratio of -99.51 and a beta of 1.66. Natera, Inc. has a 12-month low of $67.33 and a 12-month high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million for the quarter, compared to analysts' expectations of $361.43 million. During the same quarter in the previous year, the firm posted ($0.95) EPS. The firm's revenue for the quarter was up 63.9% on a year-over-year basis. As a group, equities analysts expect that Natera, Inc. will post -1.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NTRA shares. Craig Hallum lifted their price objective on Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Robert W. Baird lifted their price target on Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. Morgan Stanley upped their price objective on shares of Natera from $132.00 to $176.00 and gave the company an "overweight" rating in a report on Thursday, November 14th. StockNews.com downgraded shares of Natera from a "hold" rating to a "sell" rating in a research note on Thursday, November 14th. Finally, Piper Sandler increased their price target on shares of Natera from $150.00 to $200.00 and gave the company an "overweight" rating in a research note on Monday, November 18th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company's stock. According to data from MarketBeat, Natera presently has a consensus rating of "Moderate Buy" and a consensus target price of $165.88.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Blue Trust Inc. increased its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after buying an additional 97 shares in the last quarter. Quarry LP increased its holdings in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company's stock valued at $34,000 after acquiring an additional 190 shares in the last quarter. Versant Capital Management Inc raised its position in Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after acquiring an additional 166 shares during the last quarter. Covestor Ltd raised its position in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after acquiring an additional 95 shares during the last quarter. Finally, Principal Securities Inc. lifted its holdings in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after purchasing an additional 59 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.